LncRNA ADAMTS9-AS2 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lung Adenocarcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Travis WD. Lung cancer pathology: current concepts. Clin Chest Med. 2020;41:67–85. doi:10.1016/j.ccm.2019.11.001
   PubMed Web of Science ®Google Scholar
• Testa U, Castelli G, Pelosi E. Lung cancers: molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers. 2018;10(8):248. doi:10.3390/cancers10080248
   PubMed Web of Science ®Google Scholar
• Huo C, Zhang M-Y, Li R, et al. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma. Int J Med Sci. 2020;17(16):2427–2439. doi:10.7150/ijms.49053
   PubMed Web of Science ®Google Scholar
• Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014;1839(11):1097–1109. doi:10.1016/j.bbagrm.2014.08.012
   PubMed Web of Science ®Google Scholar
• Chen R, Xia W, Wang S, et al. Long noncoding RNA SBF2-AS1 is critical for tumorigenesis of early-stage lung adenocarcinoma. Mol Ther Nucleic Acids. 2019;16:543–553. doi:10.1016/j.omtn.2019.04.004
   PubMedGoogle Scholar
• Wang X, Li G, Luo Q, Xie J, Gan C. Integrated TCGA analysis implicates lncRNA CTB-193M12.5 as a prognostic factor in lung adenocarcinoma. Cancer Cell Int. 2018;18(1):27. doi:10.1186/s12935-018-0513-3
   PubMed Web of Science ®Google Scholar
• Herrera-Merchan A, Cuadros M, Rodriguez MI, et al. The value of lncRNA FENDRR and FOXF1 as a prognostic factor for survival of lung adenocarcinoma. Oncotarget. 2020;11(13):1172–1185. doi:10.18632/oncotarget.22154
   PubMedGoogle Scholar
• Han X, Jiang H, Qi J, et al. Novel lncRNA UPLA1 mediates tumorigenesis and prognosis in lung adenocarcinoma. Cell Death Dis. 2020;11:999. doi:10.1038/s41419-020-03198-y
   PubMed Web of Science ®Google Scholar
• Qin J, Ning H, Zhou Y, Hu Y, Yang L, Huang R. LncRNA MIR31HG overexpression serves as poor prognostic biomarker and promotes cells proliferation in lung adenocarcinoma. Biomed Pharmacother. 2018;99:363–368. doi:10.1016/j.biopha.2018.01.037
   PubMed Web of Science ®Google Scholar
• Shen FF, Zhang F, Yang HJ, et al. ADAMTS9-AS2 and CADM2 expression and association with the prognosis in esophageal squamous cell carcinoma. Biomark Med. 2020;14:1415–1426. doi:10.2217/bmm-2020-0432
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jia JP, Zhang YJ, Liu G, Zhou F, Zhang BC. Long noncoding RNA ADAMTS9-AS2 inhibits the proliferation, migration, and invasion in bladder tumor cells. Onco Targets Ther. 2020;13:7089–7100. doi:10.2147/OTT.S245826
   PubMed Web of Science ®Google Scholar
• He L, Xiao Y, Ma L, Zhao F, Yu T, Huang Y. ADAMTS9-AS2: a potential diagnostic and prognostic hallmark in prostate cancer. J BUON. 2021;26:1623–1627.
   PubMedGoogle Scholar
• Jin D, Song Y, Chen Y, Zhang P. Identification of three lncRNAs as potential predictive biomarkers of lung adenocarcinoma. Biomed Res Int. 2020;2020:7573689. doi:10.1155/2020/7573689
   PubMed Web of Science ®Google Scholar
• Liu W, Luo W, Zhou P, Cheng Y, Qian L. Bioinformatics analysis and functional verification of ADAMTS9-AS1/AS2 in lung adenocarcinoma. Front Oncol. 2021;11:681777. doi:10.3389/fonc.2021.681777
   PubMed Web of Science ®Google Scholar
• Liu C, Yang Z, Deng Z, et al. Upregulated lncRNA ADAMTS9-AS2 suppresses progression of lung cancer through inhibition of miR-223-3p and promotion of TGFBR3. IUBMB Life. 2018;70(6):536–546. doi:10.1002/iub.1752
   PubMed Web of Science ®Google Scholar
• Chen T, Zhu C, Wang X, Pan Y, Granito A. LncRNA ELF3-AS1 is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2021;2021:8323487. doi:10.1155/2021/8323487
   PubMed Web of Science ®Google Scholar
• Xu H, Wang H, Li G, Jin X, Chen B. The immune-related gene ELF3 is a novel biomarker for the prognosis of ovarian cancer. Int J Gen Med. 2021;14:5537–5548. doi:10.2147/IJGM.S332320
   PubMed Web of Science ®Google Scholar
• Liu J, Lichtenberg T, Hoadley KA, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400–416.e411.
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782–795. doi:10.1016/j.immuni.2013.10.003
   PubMed Web of Science ®Google Scholar
• Acha-Sagredo A, Uko B, Pantazi P, et al. Long non-coding RNA dysregulation is a frequent event in non-small cell lung carcinoma pathogenesis. Br J Cancer. 2020;122:1050–1058. doi:10.1038/s41416-020-0742-9
   PubMed Web of Science ®Google Scholar
• Abdul-Maksoud RS, Rashad NM, Elsayed WSH, et al. The diagnostic significance of circulating lncRNA ADAMTS9-AS2 tumor biomarker in non-small cell lung cancer among the Egyptian population. J Gene Med. 2021;e3381. doi:10.1002/jgm.3381
   PubMed Web of Science ®Google Scholar
• Wang A, Jin C, Li H, Qin Q, Li L. LncRNA ADAMTS9-AS2 regulates ovarian cancer progression by targeting miR-182-5p/FOXF2 signaling pathway. Int J Biol Macromol. 2018;120:1705–1713. doi:10.1016/j.ijbiomac.2018.09.179
   PubMed Web of Science ®Google Scholar
• Li Y, Wan Q, Wang W, et al. LncRNA ADAMTS9-AS2 promotes tongue squamous cell carcinoma proliferation, migration and EMT via the miR-600/EZH2 axis. Biomed Pharmacother. 2019;112:108719. doi:10.1016/j.biopha.2019.108719
   PubMed Web of Science ®Google Scholar
• Wang F, Tang C, Xu D, et al. LncRNA ADAMTS9-AS2 suppresses the proliferation of gastric cancer cells and the tumorigenicity of cancer stem cells through regulating SPOP. J Cell Mol Med. 2020;24:4830–4838. doi:10.1111/jcmm.15161
   PubMed Web of Science ®Google Scholar
• Liu D, Wu K, Yang Y, Zhu D, Zhang C, Zhao S. Long noncoding RNA ADAMTS9-AS2 suppresses the progression of esophageal cancer by mediating CDH3 promoter methylation. Mol Carcinog. 2020;59:32–44. doi:10.1002/mc.23126
   PubMed Web of Science ®Google Scholar
• Guo Q, Ni P, Dai Y, Hu J, Yao Y. Long-chain noncoding RNA ADAMTS9-AS2 regulates proliferation, migration, and apoptosis in bladder cancer cells through regulating miR-182-5p. J Interferon Cytokine Res. 2021;41:60–71. doi:10.1089/jir.2020.0137
   PubMed Web of Science ®Google Scholar
• Li H, Huang H, Li S, Mei H, Cao T, Lu Q. Long non-coding RNA ADAMTS9-AS2 inhibits liver cancer cell proliferation, migration and invasion. Exp Ther Med. 2021;21:559. doi:10.3892/etm.2021.9991
   PubMed Web of Science ®Google Scholar
• Liu X, Wu S, Yang Y, Zhao M, Zhu G, Hou Z. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother. 2017;95:55–61. doi:10.1016/j.biopha.2017.08.003
   PubMed Web of Science ®Google Scholar